retatrutide triple agonist gip glp-1 glucagon phase 3 2025 ๐จ Today, retatrutide, the GIP/GLP-1/glucagon agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and type 2 diabetes. ๐ Mean body weight change at 80 weeks: โฌ๏ธ ADA 2026: Retatrutide Revolution
Pay in 4 interest-free payments of $5.28 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Aug 14 - Aug 19




















,aspect=ignore)






